Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Binimetinib Combinations in Metastatic Colorectal Cancer
NCT03374254Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pembrolizumab and binimetinib in metastatic colorectal cancer (mCRC) (5 arms), sponsored by Merck & Co. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Feb 2018; status: completed.
02
Drugs
pembrolizumabbinimetinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03374254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374254.